MK-677

Application: Ibramol mesylate has been shown to increase the release of and produce sustained increases in plasma levels of several hormones including GH and insulin-like growth factor 1 (IGF-1), but without affecting cortisol levels. It is currently being developed as a potential treatment for reduced levels of these hormones, such as in children or elderly people with growth hormone deficiency, and human studies have shown increases in muscle and bone mineral density, making it a promising treatment for frail elderly people. It also changes the metabolism of body fat, so it may have applications in the treatment of obesity.